Factor VII Deficiency
A rare inherited disorder of the extrinsic coagulation pathway caused by mutations in the F7 gene, leading to variable bleeding tendencies that range from minor bruising to serious hemorrhage.
- Autosomal Recessive Inheritance
- Variable Bleeding Severity
- Specialist Hematology Care
- Estimated Prevalence
- ~1 in 500,000
- Inheritance Pattern
- Autosomal Recessive
- Gene Involved
- F7
- Care Access
- Specialist Hematology & Factor Therapy
Condition Overview
Factor VII deficiency is a rare hereditary coagulation disorder caused by mutations in the F7 gene, which encodes a protein essential for initiating the extrinsic clotting pathway. Factor VII works together with tissue factor to trigger the cascade that ultimately forms a stable blood clot.
The condition is inherited in an autosomal recessive pattern, meaning both copies of the gene must carry a mutation for symptoms to appear, though carriers with one mutated copy may have mildly reduced factor levels. Severity varies widely: some individuals with very low factor activity experience life-threatening bleeding, while others with moderate deficiency may go undiagnosed until a surgical procedure or dental extraction reveals unusual bleeding.
Because symptoms can be subtle, accurate diagnosis through coagulation testing and genetic confirmation is important, especially before surgery, childbirth, or other procedures where bleeding risk must be anticipated and managed proactively.
Types and Variants
Factor VII deficiency is classified primarily by the degree of factor activity reduction and whether the cause is inherited or acquired.
Symptoms and Signs
Symptoms of Factor VII deficiency vary widely depending on the degree of factor activity reduction.
Causes and Risk Factors
Factor VII deficiency results from disrupted production or function of clotting Factor VII, either from inherited gene mutations or acquired conditions affecting factor synthesis.
Diagnosis and Investigations
Diagnosing Factor VII deficiency involves coagulation screening tests followed by specific factor assays and, when appropriate, genetic testing.
Severity Classification
Factor VII deficiency is not staged like cancer but is classified by factor activity level, which helps guide bleeding risk assessment and treatment planning.
Standard Treatment Options
Treatment for Factor VII deficiency is tailored to bleeding severity and the clinical context, ranging from observation to factor replacement during bleeding episodes or before procedures.
Advanced and Emerging Therapies
Research into longer-acting and gene-based therapies continues to expand treatment options for rare factor deficiencies.
Recombinant Factor Replacement
Recombinant Activated Factor VII (rFVIIa)
Widely used for on-demand and perioperative bleeding control with a strong safety profile in Factor VII deficiency.
Gene Therapy Research
Investigational Gene Replacement Approaches
Early-stage research into gene therapy for inherited coagulation factor deficiencies, building on advances made in hemophilia gene therapy.
Specialist Hematology Access
Cross-Border Specialist Coordination
Access to comprehensive hemophilia and bleeding disorder treatment centers for complex or refractory cases.
Biomarkers and Laboratory Monitoring
Laboratory monitoring of Factor VII activity and related coagulation parameters guides diagnosis, treatment planning, and ongoing management.
When a Second Opinion May Be Important
Given the rarity of Factor VII deficiency, specialist input can be valuable at several key decision points.
Clinical Trials and Research
Prognosis and Outlook
With appropriate diagnosis and individualized management, most people with Factor VII deficiency can lead full, active lives, though ongoing specialist follow-up is important.
Supportive Care and Living With Factor VII Deficiency
Living well with Factor VII deficiency involves practical precautions and coordinated care to reduce bleeding risk in daily life.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Factor VII deficiency access specialist hematology review, coordinate second opinions on complex bleeding management plans, and connect with comprehensive bleeding disorder treatment centers internationally.
Get a free case reviewFrequently Asked Questions
Factor VII deficiency is a rare inherited bleeding disorder caused by mutations in the F7 gene, leading to reduced activity of a protein needed to start the blood clotting process.
No. Hemophilia A and B involve Factor VIII and Factor IX, while Factor VII deficiency is a separate, rarer condition affecting a different part of the clotting cascade.
It follows an autosomal recessive pattern, meaning a person typically needs mutations in both copies of the F7 gene to develop significant symptoms.
Easy bruising, prolonged bleeding from minor injuries, heavy menstrual bleeding, or unexpected bleeding after surgery or dental work warrant coagulation testing.
There is currently no permanent cure, but bleeding episodes and surgical risk can be effectively managed with factor replacement therapy and careful planning.
Severity varies widely; mild cases may cause no symptoms, while severe deficiency carries risk of serious spontaneous bleeding requiring specialist management.
Recombinant or plasma-derived Factor VII is typically given before and after surgery to maintain adequate clotting and reduce bleeding risk.
Yes, with coordinated care between hematology and obstetrics to manage bleeding risk during delivery and the postpartum period.
Genetic counseling and testing of close relatives can identify other affected or carrier individuals, particularly in families with known mutations.
Yes. CancerFax helps patients with Factor VII deficiency get their medical reports reviewed by specialists, coordinate second opinions, and connect with comprehensive bleeding disorder centers and advanced therapy access internationally.
Get Expert Guidance for Factor VII Deficiency
Send your medical reports for specialist hematology review and explore coordinated care options.